Assessing Trends in Cytokine-CYP Drug Interactions and Relevance to Drug Dosing.

The regulation of drug-metabolizing enzymes and transporters by cytokines has been extensively studied in vitro and in clinic. Cytokine-mediated suppression of cytochrome P450 (CYP) or drug transporters may increase or decrease the systemic clearance of drug substrates that are primarily cleared via these pathways; neutralization of cytokines by therapeutic proteins may thereby alter systemic exposures of such drug substrates. The Food and Drug Administration recommends evaluating such clinical drug interactions during clinical development and has provided labeling recommendations for therapeutic proteins.

Stochastic investigation of HIV infection and the emergence of drug resistance.

Drug-resistant HIV-1 has caused a growing concern in clinic and public health. Although combination antiretroviral therapy can contribute massively to the suppression of viral loads in patients with HIV-1, it cannot lead to viral eradication. Continuing viral replication during sub-optimal therapy (due to poor adherence or other reasons) may lead to the accumulation of drug resistance mutations, resulting in an increased risk of disease progression.

Corrigendum to "A click-ready pH-triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E" [Tetrahedron Lett. Volume 61, Issue 41, 8 October 2020, 152398].

[This corrects the article PMC7665082.].

Deterministic and stochastic models for the epidemic dynamics of COVID-19 in Wuhan, China.

In this paper, deterministic and stochastic models are proposed to study the transmission dynamics of the Coronavirus Disease 2019 (COVID-19) in Wuhan, China. The deterministic model is formulated by a system of ordinary differential equations (ODEs) that is built upon the classical SEIR framework. The stochastic model is formulated by a continuous-time Markov chain (CTMC) that is derived based on the ODE model with constant parameters.

A click-ready pH-triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E.

In this work, we developed a novel "click"-ready pH-cleavable phosphoramidate linker for controlled-release of monomethyl auristantin E (MMAE) in antibody- and small molecule-drug conjugates application. This water-soluble linker was found to have tremendous stability at physiological pHs while rapidly releasing its payload at acidic pH. The linker can also be tailored to release payloads of diverse functional groups, broadening its applications.

Optimal control in HIV chemotherapy with termination viral load and latent reservoir.

Although a number of cost-e ective strategies have been proposed for the chemotherapy of HIV infection, the termination level of viral load and latent reservoir is barely considered. However, the viral load at the termination time is an important biomarker because suppressing viral load to below the detection limit is a major objective of current antiretroviral therapy. The pool size of latently infected cells at the termination time may also play a critical role in predicting a rapid viral rebound to the pretreatment level or post-treatment control.